XOMA Royalty Completes $20.3M Acquisition of Generation Bio
Event summary
- XOMA Royalty acquired Generation Bio for $4.2913 per share in cash plus a CVR, totaling ~$20.3M for 70% of outstanding shares.
- The tender offer closed on February 6, 2026, with 4,722,533 shares tendered, meeting minimum conditions.
- Generation Bio was merged into XOMA Royalty and delisted from Nasdaq.
- XOMA Royalty now owns Generation Bio’s non-viral gene therapy delivery platform.
The big picture
XOMA Royalty’s acquisition of Generation Bio expands its royalty aggregation strategy into gene therapy, a high-growth sector. The deal reflects a broader trend of non-dilutive financing in biotech, where royalty aggregators provide capital in exchange for future economics. The $20.3M transaction underscores XOMA’s focus on acquiring pre-commercial assets with high upside potential.
What we're watching
- Platform Monetization
- How XOMA Royalty will leverage Generation Bio’s delivery platform to enhance its royalty portfolio.
- Execution Risk
- Whether XOMA can achieve anticipated net cash after winding down Generation Bio’s operations.
- Portfolio Integration
- The pace at which XOMA Royalty can develop dispositions related to Generation Bio programs.
Related topics